ATE284408T1 - Ribavirin-interferon-alpha-kombinationstherapie zur vernichtung nachweisbarer hcv-rna in chronisch hepatitis c infizierten patienten - Google Patents

Ribavirin-interferon-alpha-kombinationstherapie zur vernichtung nachweisbarer hcv-rna in chronisch hepatitis c infizierten patienten

Info

Publication number
ATE284408T1
ATE284408T1 AT99970662T AT99970662T ATE284408T1 AT E284408 T1 ATE284408 T1 AT E284408T1 AT 99970662 T AT99970662 T AT 99970662T AT 99970662 T AT99970662 T AT 99970662T AT E284408 T1 ATE284408 T1 AT E284408T1
Authority
AT
Austria
Prior art keywords
interferon
combination therapy
ribavirin
chronic hepatitis
destroy
Prior art date
Application number
AT99970662T
Other languages
English (en)
Inventor
Ashit K Ganguly
Jinping Mccormick
Raymond G Lovey
Frank Bennett
Anil K Saksena
Viyyoor M Girijavallabhan
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/348,534 external-priority patent/US6277830B1/en
Application filed by Schering Corp filed Critical Schering Corp
Application granted granted Critical
Publication of ATE284408T1 publication Critical patent/ATE284408T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/056—Triazole or tetrazole radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
AT99970662T 1998-10-16 1999-10-14 Ribavirin-interferon-alpha-kombinationstherapie zur vernichtung nachweisbarer hcv-rna in chronisch hepatitis c infizierten patienten ATE284408T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17405998A 1998-10-16 1998-10-16
US09/348,534 US6277830B1 (en) 1998-10-16 1999-07-07 5′-amino acid esters of ribavirin and the use of same to treat hepatitis C with interferon
PCT/US1999/021448 WO2000023454A1 (en) 1998-10-16 1999-10-14 Ribavirin-interferon alfa combination therapy for eradicating detectable hcv-rna in patients having chronic hepatitis c infection

Publications (1)

Publication Number Publication Date
ATE284408T1 true ATE284408T1 (de) 2004-12-15

Family

ID=26869824

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99970662T ATE284408T1 (de) 1998-10-16 1999-10-14 Ribavirin-interferon-alpha-kombinationstherapie zur vernichtung nachweisbarer hcv-rna in chronisch hepatitis c infizierten patienten

Country Status (20)

Country Link
EP (1) EP1121369B1 (de)
JP (1) JP2002527522A (de)
CN (1) CN1330658A (de)
AT (1) ATE284408T1 (de)
AU (1) AU762395B2 (de)
BR (1) BR9915546A (de)
CA (1) CA2346447C (de)
CZ (1) CZ20011130A3 (de)
DE (1) DE69922529T2 (de)
ES (1) ES2229820T3 (de)
HU (1) HUP0200447A2 (de)
ID (1) ID29187A (de)
IL (1) IL142423A0 (de)
NO (1) NO20011789L (de)
NZ (1) NZ510811A (de)
PL (1) PL347268A1 (de)
RU (1) RU2001113268A (de)
SK (1) SK4742001A3 (de)
TR (1) TR200101085T2 (de)
WO (1) WO2000023454A1 (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001255495A1 (en) 2000-04-20 2001-11-07 Schering Corporation Ribavirin-interferon alfa combination therapy for eradicating detectable hcv-rnain patients having chronic hepatitis c infection
TWI332507B (en) 2002-11-19 2010-11-01 Hoffmann La Roche Antiviral nucleoside derivatives
MXPA05010419A (es) * 2003-03-28 2006-05-31 Pharmasset Inc Compuestos para el tratamiento de infecciones por flaviviridae.
RU2371195C2 (ru) * 2003-08-13 2009-10-27 Говард Дж. Смит Энд Эссошиэйтс Пти Лтд Способ лечения вирусных инфекций
WO2005049065A2 (en) * 2003-11-19 2005-06-02 Rigel Pharmaceuticals, Inc. Synergistic combinations of dihaloacetamide with interferon or ribavirin for treatment hcv infections
WO2007027230A2 (en) 2005-05-02 2007-03-08 Rigel Pharmaceuticals, Inc. Heterocyclic anti-viral compounds comprising metabolizable moieties and their uses
US20110045535A1 (en) 2007-08-27 2011-02-24 National University Corporation Nagoya University Activator for Blood Coagulation Factor VII Promoter and Utilization of the Same
WO2009028573A1 (ja) 2007-08-27 2009-03-05 National University Corporation Nagoya University 血液凝固障害におけるリバビリンの利用
WO2011151667A1 (en) 2010-06-02 2011-12-08 Adbula Kurkayev Antiviral compositions
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
DE112012003510T5 (de) 2011-10-21 2015-03-19 Abbvie Inc. Verfahren zur Behandlung von HCV umfassend mindestens zwei direkt wirkende antivirale Wirkstoffe, Ribavirin aber nicht Interferon
GB2506085A (en) 2011-10-21 2014-03-19 Abbvie Inc Combination treatment (eg with ABT-072 or ABT-333) of DAAS for use in treating HCV
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
JP7129703B2 (ja) 2016-04-28 2022-09-02 エモリー ユニバーシティー アルキン含有ヌクレオチド及びヌクレオシド治療組成物並びにそれらに関連した使用
CN110023321A (zh) 2016-08-17 2019-07-16 索尔斯蒂斯生物有限公司 多核苷酸构建体
US11597744B2 (en) 2017-06-30 2023-03-07 Sirius Therapeutics, Inc. Chiral phosphoramidite auxiliaries and methods of their use
CN107513055B (zh) * 2017-08-11 2018-06-22 广东昊邦医药健康有限责任公司 一种利巴韦林衍生化合物及其药物组合物
US20240325419A1 (en) 2022-05-05 2024-10-03 Abdula Kurkayev Pharmaceutical composition for restoring physiological processes and cells of organism

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1482736A (en) * 1974-03-18 1977-08-10 Icn Pharmaceuticals 1-(beta-d-ribofuranosyl)-1,2,4-triazole acid derivatives
US4544741A (en) * 1982-03-29 1985-10-01 Robins Roland K Azole dinucleotide compounds and methods for their production
US4925930A (en) * 1988-11-02 1990-05-15 Nucleic Acid Research Institute Synthesis and anti-leukemic activity of alkyl-1-(β-D-ribofuranosyl)[1,2,4]triazole-3-carboximidates
GB9307043D0 (en) * 1993-04-05 1993-05-26 Norsk Hydro As Chemical compounds
US6387365B1 (en) * 1995-05-19 2002-05-14 Schering Corporation Combination therapy for chronic hepatitis C infection
EP0942916A2 (de) * 1996-11-12 1999-09-22 Medivir Aktiebolag Nukleoside

Also Published As

Publication number Publication date
JP2002527522A (ja) 2002-08-27
CZ20011130A3 (cs) 2001-08-15
NO20011789D0 (no) 2001-04-09
HUP0200447A2 (en) 2002-06-29
CA2346447C (en) 2006-01-31
CA2346447A1 (en) 2000-04-27
RU2001113268A (ru) 2003-09-27
BR9915546A (pt) 2001-08-14
NO20011789L (no) 2001-06-11
EP1121369A1 (de) 2001-08-08
IL142423A0 (en) 2002-03-10
CN1330658A (zh) 2002-01-09
TR200101085T2 (tr) 2001-08-21
DE69922529T2 (de) 2005-12-15
ID29187A (id) 2001-08-09
AU1197500A (en) 2000-05-08
DE69922529D1 (de) 2005-01-13
ES2229820T3 (es) 2005-04-16
WO2000023454A1 (en) 2000-04-27
AU762395B2 (en) 2003-06-26
PL347268A1 (en) 2002-03-25
SK4742001A3 (en) 2001-11-06
EP1121369B1 (de) 2004-12-08
NZ510811A (en) 2003-06-30

Similar Documents

Publication Publication Date Title
ATE284408T1 (de) Ribavirin-interferon-alpha-kombinationstherapie zur vernichtung nachweisbarer hcv-rna in chronisch hepatitis c infizierten patienten
NZ507621A (en) HCV-RNA eradication in antiviral treatment naive patients having HCV genotypes 1, 2 or 3 using ribavirin and interferon alpha combination therapy
MY117781A (en) Combination therapy for eradicating detectable hcv-rna in patients having chronic hepatitis c infection
WO2000037110A3 (en) Ribavirin-pegylated interferon alfa induction hcv combination therapy
IL153078A0 (en) Methods for treating hepatitis delta virus infection with beta-l-2' deoxy nucleosides
AR021226A1 (es) Terapia combinatoria con ribavirina-interferon alfa para erradicar el hcv-rna detectable en aquellos pacientes que presentan infeccion porhepatitis c cronica
BR0009840A (pt) Terapia de combinação para hcv, contendo ribavirina em associação com antioxidantes
YU92102A (sh) Metode i smeše za lečenje virusnog hepatitisa c
NZ309217A (en) Ribavirin and interferon alpha for the treatment of hepatitis C
PE20001386A1 (es) Terapia de combinacion para el vhc por induccion de ribavirina-interferon alfa
ECSP993178A (es) Terapia combinatoria con ribarvirina -interferon alfa para erradicar el hcv - rna detectable en aquellos pacientes que presentan infeccion por hepatitis c cronica
DE60125377D1 (de) Behandlung von hepatitis c mit thymosin, interferon und ribavirin
TH52792A3 (th) การรักษาแบบการรวมกันของไรบาวิรีน-อินเตอร์เฟอรอนอัลฟา เพื่อทำลาย hcv-rna ที่ตรวจหาได้ในผู้ป่วยที่มีการติดเชื้อตับอักเสบ c เรื้อรัง
ECSP982669A (es) Terapia en combinacion para erradicar vhc -arn detectable en pacientes que padecen infeccion de hetatitis c cronica
TH52792B (th) การรักษาแบบการรวมกันของไรบาวิริน-อินเตอร์เฟอรอนอัลฟา เพื่อทำลาย hcv-rna ที่ตรวจหาได้ในผู้ป่วยที่มีการ

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties